Three treatments for psoriatic arthritis are recommended in final draft guidance published by the National Institute of Health and Clinical Excellence (NICE). Etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) are proposed for treating adults with active and progressive psoriatic arthritis when specified criteria are met...

The National Institute for Health and Clinical Excellence (NICE) has published draft guidance recommending etanercept (Enbrel, Wyeth Pharmaceuticals) and adalimumab (Humira, Abbott Laboratories) for the treatment of adults with active and progressive psoriatic arthritis when specific criteria are met...

Enbrel is the trade name for Etanercept, a medication used for treating autoimmune diseases. Enbrel is a TNF (tumor necrosis factor) inhibitor; it interferes with TNF…

Enbrel (etanercept), Wyeth's biological treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, is now available as a new easy-to-use pre-filled auto-injector device, known as the Enbrel MYCLIC pen. The Enbrel MYCLIC pen is a single-use auto-injector, designed to deliver Enbrel as a 50mg subcutaneous injection...

Enbrel (etanercept), Wyeth's biological treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, is now available as a new easy-to-use pre-filled auto-injector device, known as the Enbrel MYCLIC pen. The Enbrel MYCLIC pen is a single-use auto-injector, designed to deliver Enbrel as a 50mg subcutaneous injection...